Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers

Next Previous
X
Search
Trial Profile

A randomised, Phase 1, double-blind, placebo-controlled single and multiple ascending dose study to assess the safety, tolerability and pharmockinetics of PBT434 in healthy volunteers

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 13 Feb 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs ATH 434 (Primary)
  • Indications Multiple system atrophy; Parkinson's disease
  • Focus Adverse reactions; First in man
  • Acronyms PBT434-101
  • Sponsors Alterity Therapeutics

    • Most Recent Events

    • 13 Feb 2025 According to an Alterity Therapeutics media release, company announced that it has received binding commitments for a capital raising of A$40.0 million via a two tranche placement to Australian and international institutions and other unrelated sophisticated, professional or exempt investors. Funds to be used primarily to advance development of ATH434 .
    • 09 Nov 2021 According to an Alterity Therapeutics media release, data from the study has been presented at the American Autonomic Society 32nd Annual International Symposium on the Autonomic Nervous System 2021.
    • 09 Nov 2021 Results presented in an Alterity Therapeutics media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top